Chimpanzee adenovirus vector-based avian influenza vaccine completely protects mice against lethal challenge of H5N1

Vaccine

Volumn 34, Issue 41, 2016, Pages 4875-4883

  Cheng, Tao ^a   Wang, Xiang ^a   Song, Yufeng ^a   Tang, Xinying ^a   Zhang, Chao ^a   Zhang, Hongbo ^a   Jin, Xia ^a   Zhou, Dongming ^a  

^a INSTITUTE PASTEUR OF SHANGHAI   (China)

Author keywords

AdC7; H5N1; Immune responses; Influenza; Vaccine

Indexed keywords

ADENOVIRUS VECTOR; AVIAN INFLUENZA VACCINE; INFLUENZA VIRUS HEMAGGLUTININ; NEUTRALIZING ANTIBODY; INFLUENZA VACCINE; VIRUS ANTIBODY;

ADULT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELLULAR IMMUNITY; CONTROLLED STUDY; FEMALE; HIGHLY PATHOGENIC AVIAN INFLUENZA; HUMAN; HUMAN CELL; HUMORAL IMMUNITY; INFLUENZA A VIRUS (H5N1); LUNG PARENCHYMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; VIRUS LOAD; VIRUS REPLICATION; ANIMAL; BAGG ALBINO MOUSE; BLOOD; CD8+ T LYMPHOCYTE; HEK293 CELL LINE; IMMUNOLOGY; INSTITUTE FOR CANCER RESEARCH MOUSE; ORTHOMYXOVIRUS INFECTION; PAN TROGLODYTES; PASSIVE IMMUNIZATION; SIMIAN VIRUS;

ADENOVIRUSES, SIMIAN; ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; CD8-POSITIVE T-LYMPHOCYTES; FEMALE; HEK293 CELLS; HEMAGGLUTININ GLYCOPROTEINS, INFLUENZA VIRUS; HUMANS; IMMUNITY, CELLULAR; IMMUNITY, HUMORAL; IMMUNIZATION, PASSIVE; INFLUENZA A VIRUS, H5N1 SUBTYPE; INFLUENZA VACCINES; MICE; MICE, INBRED BALB C; MICE, INBRED ICR; ORTHOMYXOVIRIDAE INFECTIONS; PAN TROGLODYTES;

EID: 84990060966     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2016.08.066     Document Type: Article

References (43)

1. [1] Xu, X.Y., Subbarao, K., Cox, N.J., Guo, Y.J., Genetic characterization of the pathogenic influenza A/Goose/Guangdong/1/96 (H5N1) virus: similarity of its hemagglutinin gene to those of H5N1 viruses from the 1997 outbreaks in Hong Kong. Virology 261 (1999), 15–19.
2. [2] Yuen, K.Y., Chan, P.K., Peiris, M., Tsang, D.N., Que, T.L., Shortridge, K.F., et al. Clinical features and rapid viral diagnosis of human disease associated with avian influenza A H5N1 virus. Lancet 351 (1998), 467–471.
3. [3] Nicholson, K.G., Wood, J.M., Zambon, M., Influenza. Lancet 362 (2003), 1733–1745.
4. [4] Ducatez, M.F., Olinger, C.M., Owoade, A.A., Tarnagda, Z., Tahita, M.C., Sow, A., et al. Molecular and antigenic evolution and geographical spread of H5N1 highly pathogenic avian influenza viruses in western Africa. J Gen Virol 88 (2007), 2297–2306.
5. [5] Organization WH. Cumulative number of confirmed human cases of avian influenza A/(H5N1) reported to WHO. < http://www.who.int/influenza/human_animal_interface/EN_GIP_20151214cumulativeNumberH5N1cases.pdf?ua=1>.
6. [6] Ungchusak, K., Auewarakul, P., Dowell, S.F., Kitphati, R., Auwanit, W., Puthavathana, P., et al. Probable person-to-person transmission of avian influenza A (H5N1). New Engl J Med 352 (2005), 333–340.
7. [7] Imai, M., Watanabe, T., Hatta, M., Das, S.C., Ozawa, M., Shinya, K., et al. Experimental adaptation of an influenza H5 HA confers respiratory droplet transmission to a reassortant H5 HA/H1N1 virus in ferrets. Nature, 486, 2012 420-+.
8. [8] Herfst, S., Schrauwen, E.J.A., Linster, M., Chutinimitkul, S., de Wit, E., Munster, V.J., et al. Airborne transmission of influenza A/H5N1 virus between ferrets. Science 336 (2012), 1534–1541.
9. [9] Talaat, K.R., Luke, C.J., Khurana, S., Manischewitz, J., King, L.R., McMahon, B.A., et al. A live attenuated influenza A(H5N1) vaccine induces long-term immunity in the absence of a primary antibody response. J Infect Dis 209 (2014), 1860–1869.
10. [10] Subbarao, K., Chen, H., Swayne, D., Mingay, L., Fodor, E., Brownlee, G., et al. Evaluation of a genetically modified reassortant H5N1 influenza A virus vaccine candidate generated by plasmid-based reverse genetics. Virology 305 (2003), 192–200.
11. [11] Zhou, F., Wang, G., Buchy, P., Cai, Z., Chen, H., Chen, Z., et al. A triclade DNA vaccine designed on the basis of a comprehensive serologic study elicits neutralizing antibody responses against all clades and subclades of highly pathogenic avian influenza H5N1 viruses. J Virol 86 (2012), 6970–6978.
12. [12] Hoelscher, M.A., Garg, S., Bangari, D.S., Belser, J.A., Lu, X., Stephenson, I., et al. Development of adenoviral-vector-based pandemic influenza vaccine against antigenically distinct human H5N1 strains in mice. Lancet 367 (2006), 475–481.
13. [13] Ilyinskii, P., Thoidis, G., Shneider, A., Development of a vaccine against pandemic influenza viruses: current status and perspectives. Int Rev Immunol 27 (2008), 392–426.
14. [14] Vemula, S.V., Mittal, S.K., Production of adenovirus vectors and their use as a delivery system for influenza vaccines. Exp Opin Biol Ther 10 (2010), 1469–1487.
15. [15] Gao, W.T., Soloff, A.C., Lu, X.H., Montecalvo, A., Nguyen, D.C., Matsuoka, Y., et al. Protection of mice and poultry from lethal H5N1 avian influenza virus through adenovirus-based immunization. J Virol 80 (2006), 1959–1964.
16. [16] Wesley, R.D., Tang, M., Lager, K.M., Protection of weaned pigs by vaccination with human adenovirus 5 recombinant viruses expressing the hemagglutinin and the nucleoprotein of H3N2 swine influenza virus. Vaccine 22 (2004), 3427–3434.
17. [17] Van Kampen, K.R., Shi, Z.K., Gao, P., Zhang, J.F., Foster, K.W., Chen, D.T., et al. Safety and immunogenicity of adenovirus-vectored nasal and epicutaneous influenza vaccines in humans. Vaccine 23 (2005), 1029–1036.
18. [18] Wang, X., Xing, M., Zhang, C., Yang, Y., Chi, Y.D., Tang, X.Y., et al. Neutralizing antibody responses to enterovirus and adenovirus in healthy adults in China. Emerg Microbes Infec, 3, 2014.
19. [19] Holterman, L., Vogels, R., van der Vlugt, R., Sieuwerts, M., Grimbergen, J., Kaspers, J., et al. Novel replication-incompetent vector derived from adenovirus type 11 (Ad11) for vaccination and gene therapy: low seroprevalence and non-cross-reactivity with Ad5. J Virol 78 (2004), 13207–13215.
20. [20] Lorin, C., Vanloubbeeck, Y., Baudart, S., Ska, M., Bayat, B., Brauers, G., et al. Heterologous prime-boost regimens with a recombinant chimpanzee adenoviral vector and adjuvanted F4 protein elicit polyfunctional HIV-1-specific T-Cell responses in macaques. PLoS ONE, 10, 2015, e0122835.
21. [21] Kobinger, G.P., Feldmann, H., Zhi, Y., Schumer, G., Gao, G.P., Feldmann, F., et al. Chimpanzee adenovirus vaccine protects against Zaire Ebola virus. Virology 346 (2006), 394–401.
22. [22] Parzych, E.M., DiMenna, L.J., Latimer, B.P., Small, J.C., Kannan, S., Manson, B., et al. Influenza virus specific CD8(+) T cells exacerbate infection following high dose influenza challenge of aged mice. Biomed Res Int, 2013.
23. [23] Zhang, H., Tang, X., Zhu, C., Song, Y., Yin, J., Xu, J., et al. Adenovirus-mediated artificial MicroRNAs targeting matrix or nucleoprotein genes protect mice against lethal influenza virus challenge. Gene Ther 22 (2015), 653–662.
24. [24] Zhou, D.M., Wu, T.L., Lasaro, M.O., Latimer, B.P., Parzych, E.M., Bian, A., et al. A universal influenza A vaccine based on adenovirus expressing matrix-2 ectodomain and nucleoprotein protects mice from lethal challenge. Mol Ther 18 (2010), 2182–2189.
25. [25] Zhou, D.M., Zhou, X.Y., Bian, A., Li, H., Chen, H., Small, J.C., et al. An efficient method of directly cloning chimpanzee adenovirus as a vaccine vector. Nat Protoc 5 (2010), 1775–1785.
26. [26] Farina, S.F., Gao, G.P., Xiang, Z.Q., Rux, J.J., Burnett, R.M., Alvira, M.R., et al. Replication-defective vector based on a chimpanzee adenovirus. J Virol 75 (2001), 11603–11613.
27. [27] Kodihalli, S., Goto, H., Kobasa, D.L., Krauss, S., Kawaoka, Y., Webster, R.G., DNA vaccine encoding hemagglutinin provides protective immunity against H5N1 influenza virus infection in mice. J Virol 73 (1999), 2094–2098.
28. [28] Song, Y.F., Wang, X., Zhang, H.B., Tang, X.Y., Li, M., Yao, J.F., et al. Repeated low-dose influenza virus infection causes severe disease in mice: a model for vaccine evaluation. J Virol 89 (2015), 7841–7851.
29. [29] Du, L.Y., Zhao, G.Y., Sun, S.H., Zhang, X.J., Zhou, X.J., Guo, Y., et al. A critical HA1 neutralizing domain of H5N1 influenza in an optimal conformation induces strong cross-protection. PLoS ONE, 2013, 8.
30. [30] La Linn, M., Mateo, L., Gardner, J., Suhrbier, A., Alphavirus-specific cytotoxic T lymphocytes recognize a cross-reactive epitope from the capsid protein and can eliminate virus from persistently infected macrophages. J Virol 72 (1998), 5146–5153.
31. [31] Wilson, J.M., Adenoviruses as gene-delivery vehicles. New Engl J Med 334 (1996), 1185–1187.
32. [32] Fitzgerald, J.C., Gao, G.P., Reyes-Sandoval, A., Pavlakis, G.N., Xiang, Z.Q., Wlazlo, A.P., et al. A simian replication-defective vaccine to HIV-1 gag. J Immunol 170 (2003), 1416–1422.
33. [33] Buchbinder, S.P., Mehrotra, D.V., Duerr, A., Fitzgerald, D.W., Mogg, R., Li, D., et al. Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial. Lancet 372 (2008), 1881–1893.
34. [34] Fellay, J., Shianna, K.V., Cirulli, E.T., McElrath, J., Casimiro, D.R., Geraghty, D.E., et al. A genome-wide association study of host genetic determinants of T cell responses to the MRKAd5 HIV-1 gag/pol/nef vaccine in the STEP trial. Retrovirology, 6, 2009.
35. [35] Cohen, C.J., Xiang, Z.Q., Gao, G.P., Ertl, H.C.J., Wilson, J.M., Bergelson, J.M., Chimpanzee adenovirus CV-68 adapted as a gene delivery vector interacts with the coxsackievirus and adenovirus receptor. J Gen Virol 83 (2002), 151–155.
36. [36] Tatsis, N., Tesema, L., Robinson, E.R., Giles-Davis, W., McCoy, K., Gao, G.P., et al. Chimpanzee-origin adenovirus vectors as vaccine carriers. Gene Ther 13 (2006), 421–429.
37. [37] Subbarao, K., Chen, H.L., Swayne, D., Mingay, L., Fodor, E., Brownlee, G., et al. Evaluation of a genetically modified reassortant H5N1 influenza A virus vaccine candidate generated by plasmid-based reverse genetics. Virology 305 (2003), 192–200.
38. [38] Roos, A., Roozendaal, R., Theeuwsen, J., Riahi, S., Vaneman, J., Tolboom, J., et al. Protection against H5N1 by multiple immunizations with seasonal influenza vaccine in mice is correlated with H5 cross-reactive antibodies. Vaccine 33 (2015), 1739–1747.
39. [39] McCoy, K., Tatsis, N., Korioth-Schmitz, B., Lasaro, M.O., Hensley, S.E., Lin, S.W., et al. Effect of preexisting immunity to adenovirus human serotype 5 antigens on the immune responses of nonhuman primates to vaccine regimens based on human- or chimpanzee-derived adenovirus vectors. J Virol 81 (2007), 6594–6604.
40. [40] Yap, K.L., Ada, G.L., Mckenzie, I.F.C., Transfer of specific cytotoxic T-lymphocytes protects mice inoculated with influenza-virus. Nature 273 (1978), 238–239.
41. [41] Epstein, S.L., Kong, W.P., Misplon, J.A., Lo, C.Y., Tumpey, T.M., Xu, L., et al. Protection against multiple influenza A subtypes by vaccination with highly conserved nucleoprotein. Vaccine 23 (2005), 5404–5410.
42. [42] Deng, Y.P., Yewdell, J.W., Eisenlohr, L.C., Bennink, J.R., MHC affinity, peptide liberation, T cell repertoire, and immunodominance all contribute to the paucity of MHC class I-restricted peptides recognized by antiviral CTL. J Immunol 158 (1997), 1507–1515.
43. [43] Hoelscher, M.A., Jayashankar, L., Garg, S., Veguilla, V., Lu, X., Singh, N., et al. New pre-pandemic influenza vaccines: an egg- and adjuvant-independent human adenoviral vector strategy induces long-lasting protective immune responses in mice. Clin Pharmacol Ther 82 (2007), 665–671.